Search

Harmony Biosciences Holdings Inc

Închisă

SectorSănătate

38.13 0.55

Rezumat

Modificarea prețului

24h

Curent

Minim

37.86

Maxim

38.28

Indicatori cheie

By Trading Economics

Venit

43M

75M

Vânzări

46M

261M

P/E

Medie Sector

12.343

57.371

EPS

1.28

Marjă de profit

28.87

Angajați

293

EBITDA

53M

102M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+9.12% upside

Dividende

By Acuity

Următoarele câștiguri

3 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

160M

2.2B

Deschiderea anterioară

37.58

Închiderea anterioară

38.13

Sentimentul știrilor

By Acuity

50%

50%

150 / 340 Clasament în Healthcare

Harmony Biosciences Holdings Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 aug. 2026, 22:31 UTC

Harmony Biosciences Holdings Inc. is trading higher in after-market hours, reaching the upper end of its one-month range and above the 20-day moving average.

20 aug. 2026, 23:31 UTC

Harmony Biosciences Holdings Inc shares are higher in after-market trading, supported by strong momentum above the 20-day moving average and within its one-month range.

19 aug. 2026, 19:56 UTC

Harmony Biosciences Holdings Inc. is trading higher, reaching a session high and remaining above its 20-day moving average during Wednesday's session.

14 aug. 2026, 19:46 UTC

Harmony Biosciences shares are lower as the Pharmaceuticals sub-sector declines. The stock remains above its 20-day moving average, indicating some underlying strength.

13 aug. 2026, 22:51 UTC

Harmony Biosciences shares are rising in after-market trading, supported by favorable macroeconomic indicators and a broader trend in major averages closing higher.

11 aug. 2026, 19:21 UTC

Harmony Biosciences Holdings Inc. is trading higher today, continuing its upward trajectory since Monday's close amid broader market trends and rising oil prices.

10 aug. 2026, 19:46 UTC

Harmony Biosciences Holdings Inc is trading higher, continuing its upward trend since Friday. The stock remains above its 20-day moving average.

7 aug. 2026, 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

6 aug. 2026, 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5 aug. 2026, 20:03 UTC

Social Media
Event
News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4 aug. 2026, 20:04 UTC

Social Media
News
Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3 aug. 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1 aug. 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 iul. 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 iul. 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 iul. 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 iul. 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 iul. 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 iul. 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Comparație

Modificare preț

Harmony Biosciences Holdings Inc Așteptări

Obiectiv de preț

By TipRanks

9.12% sus

Prognoză pe 12 luni

Medie 41.63 USD  9.12%

Maxim 55 USD

Minim 30 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHarmony Biosciences Holdings Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

3

Cumpărare

4

Păstrare

1

Vânzare

Sentiment

By Acuity

150 / 340 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat